ArticleMolecular pharmaceutics2025
Intratumoral Immunotherapy with Cowpea Mosaic Virus and Interleukin-12 Eliminates Established Treated Tumors and Generates Robust Systemic Immunity to Suppress the Growth of Untreated Metastatic Tumors.
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structure-function relationship of S protein cleavage in cowpea mosaic virus intratumoral immunotherapy.Biomaterials science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Intratumoral immunotherapy (ITIT) delivers immune-stimulating agents or treatments directly into solid tumors to reverse the immunosuppressive nature of the tumor microenvironment (TME) and enables local and systemic antitumor immunity. However, optimal clinical strategies for ITIT are not yet fully understood. Cowpea mosaic virus (CPMV) is a plant virus that is not infectious in mammals but is a powerful multi-toll-like receptor (TLR) agonist which stimulates potent antitumor immunity when used in ITIT. ITIT by transfection of interleukin-12 (IL-12) expressing plasmids into melanoma tumors
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.